7 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
A Phase Ib/II study of MEK1/2 inhibitor PD-0325901 or MEK-162 with cMET inhibitor PF-02341066 in RASMT and RASWT (with aberrant c-MET) Colorectal Cancer Patients (MERCURIC)
Date du début: 1 déc. 2013, Date de fin: 30 nov. 2020,
Colorectal cancer (CRC) is the 3rd most common cancer in Europe, and with approximately 200,000 deaths per year, it remains the 2nd most common cause of cancer death. More than half of all CRC patients develop distant metastases and have 5-year overall survival (OS) of less than 5% because of ineffective treatments. Increased understanding of cancer biology, coupled with the implementation of “omi ...
Voir le projet
13
Participants partenaires
TERMINÉ
iABC Programme (IABC PROGRAMME)
Date du début: 1 août 2015, Date de fin: 31 juil. 2020,
Cystic Fibrosis (CF) is a common fatal inherited disease with a frequency of 1 in 2500 live births, affecting approximately 36,000 (0.737/10,000) people in the EU. Chronic bacterial pulmonary infection leading to an irreversible decline in lung structure and function is the main cause of mortality and morbidity in patients with CF, with more than 95% of deaths due to respiratory failure. Pseudomon ...
Voir le projet
21
Participants partenaires
TERMINÉ
Novel Stromal Cell Therapy for Diabetic Kidney Disease (NEPHSTROM)
Date du début: 1 mai 2015, Date de fin: 30 avr. 2019,
Type 2 diabetes will affect >500 million adults by 2040 and its secondary complications will generate enormous socioeconomic costs - in particular, diabetic kidney disease (DKD), which is already the most common cause of chronic kidney disease. DKD is associated with greatly increased mortality and frequently progresses to end stage renal failure. Pharmacotherapy, dialysis and transplantation repr ...
Voir le projet
12
Participants partenaires
TERMINÉ
Epilepsy Pharmacogenomics: delivering biomarkers for clinical use (EpiPGX)
Date du début: 1 nov. 2011, Date de fin: 31 oct. 2015,
The purpose of the project is to identify genome-based biomarkers for use in clinical practice to individualise treatment of epilepsy, and stratify patients for clinical trials, aiming to avoid chronicity, prevent relapse and reduce adverse drug reactions (ADRs).The need for improved treatments in epilepsy is undoubted. Epilepsy is affects 50,000,000 people of all ages worldwide. Epilepsy is serio ...
Voir le projet
15
Participants partenaires
TERMINÉ
Efficacy and Safety of Inhaled Budesonide in Very Preterm Infants at Risk for Bronchopulmonary Dysplasia (NEUROSIS)
Date du début: 1 mars 2009, Date de fin: 31 août 2015,
HYPOTHESIS: Early inhalation of Budesonide (BS) reduces the absolute risk of developing bronchopulmonary dysplasia (BPD) or death in preterm infants born between 23 and 27 weeks gestational age (GA) by 10%. PRIMARY OBJECTIVE: Survival without BPD at 36 weeks GA. SECONDARY OBJECTIVES: (1) neurodevelopment at a corrected age of 18-22 months; (2) adverse treatment effects; (3) mortality at 36 weeks G ...
Voir le projet
15
Participants partenaires
TERMINÉ
Intelligent System for independent living and self-care of seniors with cognitive problems or mild dementia (ISISEMD)
Date du début: 1 mars 2009, Date de fin: 31 août 2011,
The aim of the ISISEMD project is to provide a pilot of innovative intelligent set of scalable services that will support the independent living of elderly people in general and in particular the group of elderly with cognitive problems or mild dementia and at the same time to support the formal and informal caregivers in their daily interaction with the elderly. The services will improve the elde ...
Voir le projet
15
Participants partenaires
TERMINÉ
"European Networks of Centres of Expertise for CF (Cystic Fibrosis), LAM (Lymphangioleiomyomatosis), and LTX (Lung Transplantation)" (ENCE-CF-LAM-LTX)
Date du début: 1 avr. 2009, Date de fin: 31 mars 2011,
"European Centres of Expertise Networks for rare diseases have been identified by the European Commission as one important area of future activity in the attempt of achieving one of the main objectives across the EC endeavour of “Optimising the delivery of health care to European Citizens”. It is obvious that especially in rare diseases the joined forces of the experts networking throughout Europe ...
Voir le projet